{ "run": { "id": "cmnqyvhdz00j6p658w3edkxay", "region": "BR", "assetId": "cmnqyvhdm00j2p658iztl7x6w", "ticker": "HYPE3", "snapshotId": "cmnqyvhdr00j4p658dolbeqq3", "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux", "createdAt": "2026-04-09T04:18:20.229Z", "promptTemplate": { "id": "cmnqt07si0005lm3jzpxuu1ux", "name": "Oficial 08.apr.2026", "version": 1 }, "snapshot": { "id": "cmnqyvhdr00j4p658dolbeqq3", "assetId": "cmnqyvhdm00j2p658iztl7x6w", "asOf": "2026-04-08T21:30:33.000Z", "snapshot": { "asOf": "2026-04-08T21:30:33.000Z", "quote": { "asOf": "2026-04-08T21:30:33.000Z", "open": 24.21, "price": 23.77, "dayLow": 23.62, "volume": 3977700, "dayHigh": 24.35, "currency": "BRL", "prevClose": 23.66, "week52Low": 18.99009901, "week52High": 28.58415842 }, "fundamentals": { "pe": 12.80366280635605, "beta": 0, "epsTTM": 1.869718, "fcfTTM": 1343921000, "growth": { "epsYoy": 14.072976, "revenueYoy": 4.095435 }, "sector": "Consumo Não Cíclico", "margins": { "net": 0.15457952, "gross": 0.5903902, "operating": 0.22915184 }, "website": "https://www.hypera.com.br", "industry": "Medicamentos e Outros Produtos", "pegRatio": 0.008777814, "ebitdaTTM": 2081499000, "forwardPe": 0, "marketCap": 16327671955, "totalCash": 1645541000, "totalDebt": 9834085000, "debtEquity": 0.7851957, "quickRatio": 0.9655118, "revenueTTM": 7699157000, "companyName": "Hypera S.A.", "priceToBook": 1.1738468, "currentRatio": 1.471275, "dividendYield": 0.0983508624316365, "returnOnAssets": 0.047306295, "returnOnEquity": 0.09502527, "analystOpinions": 0, "businessSummary": "A Hypera S.A., listada na B3 sob o ticker HYPE3, é uma farmacêutica brasileira com foco em medicamentos de prescrição, isentos de prescrição e marcas de saúde. A companhia foi fundada em 2001 e, após reestruturações de portfólio, consolidou atuação prioritária no setor farmacêutico.\n\nO modelo de negócios combina desenvolvimento, produção, marketing e distribuição de produtos para diferentes classes terapêuticas, com presença forte em canais de varejo e prescrição médica. A empresa opera marcas consolidadas no mercado doméstico e mantém estrutura industrial e comercial em escala nacional.\n\nNos últimos anos, a estratégia incluiu aquisições de portfólios e marcas para ampliar participação em categorias de maior rentabilidade, além de ganhos de eficiência fabril e logística. O foco permanece em expansão de receita por mix de produtos e execução comercial.\n\nNo contexto do mercado brasileiro, …", "enterpriseValue": 22890240000, "analystTargetLow": 0, "analystTargetHigh": 0, "analystTargetMean": 0, "fullTimeEmployees": 9399, "sharesOutstanding": 633420800, "enterpriseToEbitda": 10.996998, "analystTargetMedian": 0, "enterpriseToRevenue": 2.973084, "operatingCashflowTTM": 2574431000, "analystRecommendationKey": null } }, "createdAt": "2026-04-09T04:18:20.223Z" }, "results": [ { "id": "cmnqyvhe100j8p658acp90frr", "runId": "cmnqyvhdz00j6p658w3edkxay", "modelId": "anthropic", "status": "SUCCESS", "rawOutput": "{\"model\":\"claude-sonnet-4-20250514\",\"as_of\":\"2026-04-08T21:30:33.000Z\",\"ticker\":\"HYPE3\",\"currency\":\"BRL\",\"current_price\":23.77,\"target_price_6m\":26.0,\"target_price_12m\":28.0,\"recommendation\":\"BUY\",\"confidence\":0.62,\"thesis_bullets\":[\"Largest Brazilian pharma trading at attractive 12.8x P/E with 9.8% dividend yield\",\"Working capital restructuring improved FCF generation to BRL 1.34B TTM\",\"EPS growing 14% YoY despite modest 4% revenue growth signals margin discipline\",\"Stock near 52-week low offers entry point with defensive sector positioning\",\"Deleveraging path from BRL 9.8B debt should unlock further shareholder returns\"],\"key_drivers\":[{\"driver\":\"Working capital optimization boosting cash conversion\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Margin expansion from product mix toward higher-value Rx portfolio\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"High dividend yield providing downside support\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Elevated gross debt at BRL 9.8B constraining flexibility\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Modest top-line growth of ~4% limits re-rating speed\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Defensive pharma sector positioning in volatile macro\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Brazilian interest rate environment impacting cost of debt\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Brand portfolio consolidation driving operating leverage\",\"impact\":\"MED\",\"direction\":\"POS\"}],\"risks\":[\"Debt servicing costs rise if Selic stays elevated, pressuring net income\",\"Revenue growth stalls below inflation as generics competition intensifies\",\"Working capital gains prove one-time, FCF normalizes lower\",\"Regulatory changes in Brazilian pharma pricing or distribution\",\"Acquisition integration risks if M&A strategy resumes\",\"Currency depreciation impact on imported API costs\"],\"assumptions\":{\"revenue_cagr_3y\":0.06,\"ebit_margin_target\":0.24,\"wacc\":0.13,\"terminal_multiple\":12.0},\"scenarios\":{\"bear\":{\"target_price\":21.0,\"prob\":0.2,\"notes\":\"P/E compresses to 10x on debt concerns and stagnant top-line growth.\"},\"base\":{\"target_price\":28.0,\"prob\":0.55,\"notes\":\"EPS grows ~12% with modest re-rating to 13.5x as deleveraging progresses.\"},\"bull\":{\"target_price\":33.0,\"prob\":0.25,\"notes\":\"Strong execution drives 15x P/E re-rating plus accelerated debt reduction.\"}},\"method_notes\":\"Earnings-power valuation anchored on forward P/E (13-14x on ~BRL 2.05 FY EPS) cross-checked with EV/EBITDA and FCF yield (~8.2%). 12M target implies ~17.8% return supporting BUY. High dividend yield (9.8%) provides margin of safety. Key uncertainty is pace of deleveraging vs growth investment. Confidence capped at 0.62 due to elevated leverage and modest organic growth. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T21:30:33.000Z", "model": "claude-sonnet-4-20250514", "risks": [ "Debt servicing costs rise if Selic stays elevated, pressuring net income", "Revenue growth stalls below inflation as generics competition intensifies", "Working capital gains prove one-time, FCF normalizes lower", "Regulatory changes in Brazilian pharma pricing or distribution", "Acquisition integration risks if M&A strategy resumes", "Currency depreciation impact on imported API costs" ], "ticker": "HYPE3", "currency": "BRL", "scenarios": { "base": { "prob": 0.55, "notes": "EPS grows ~12% with modest re-rating to 13.5x as deleveraging progresses.", "target_price": 28 }, "bear": { "prob": 0.2, "notes": "P/E compresses to 10x on debt concerns and stagnant top-line growth.", "target_price": 21 }, "bull": { "prob": 0.25, "notes": "Strong execution drives 15x P/E re-rating plus accelerated debt reduction.", "target_price": 33 } }, "confidence": 0.62, "assumptions": { "wacc": 0.13, "revenue_cagr_3y": 0.06, "terminal_multiple": 12, "ebit_margin_target": 0.24 }, "key_drivers": [ { "driver": "Working capital optimization boosting cash conversion", "impact": "HIGH", "direction": "POS" }, { "driver": "Margin expansion from product mix toward higher-value Rx portfolio", "impact": "HIGH", "direction": "POS" }, { "driver": "High dividend yield providing downside support", "impact": "MED", "direction": "POS" }, { "driver": "Elevated gross debt at BRL 9.8B constraining flexibility", "impact": "HIGH", "direction": "NEG" }, { "driver": "Modest top-line growth of ~4% limits re-rating speed", "impact": "MED", "direction": "NEG" }, { "driver": "Defensive pharma sector positioning in volatile macro", "impact": "MED", "direction": "POS" }, { "driver": "Brazilian interest rate environment impacting cost of debt", "impact": "MED", "direction": "NEG" }, { "driver": "Brand portfolio consolidation driving operating leverage", "impact": "MED", "direction": "POS" } ], "method_notes": "Earnings-power valuation anchored on forward P/E (13-14x on ~BRL 2.05 FY EPS) cross-checked with EV/EBITDA and FCF yield (~8.2%). 12M target implies ~17.8% return supporting BUY. High dividend yield (9.8%) provides margin of safety. Key uncertainty is pace of deleveraging vs growth investment. Confidence capped at 0.62 due to elevated leverage and modest organic growth. Not investment advice.", "current_price": 23.77, "recommendation": "BUY", "thesis_bullets": [ "Largest Brazilian pharma trading at attractive 12.8x P/E with 9.8% dividend yield", "Working capital restructuring improved FCF generation to BRL 1.34B TTM", "EPS growing 14% YoY despite modest 4% revenue growth signals margin discipline", "Stock near 52-week low offers entry point with defensive sector positioning", "Deleveraging path from BRL 9.8B debt should unlock further shareholder returns" ], "target_price_6m": 26, "target_price_12m": 28 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "anthropic", "webSearch": { "enabled": false, "maxToolCalls": 2, "disabledReason": null }, "pauseTurns": 0, "stopReason": "end_turn" }, "sanityIssues": [] }, "latencyMs": 38658, "createdAt": "2026-04-09T04:18:20.229Z", "usage": { "inputTokens": 3753, "outputTokens": 1935, "costUsd": 0.06714 } }, { "id": "cmnqyvhe100jbp6588vkbfbfb", "runId": "cmnqyvhdz00j6p658w3edkxay", "modelId": "deepseek.reasoner", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"Equity Research Model\",\n \"as_of\": \"2026-04-08T21:30:33.000Z\",\n \"ticker\": \"HYPE3\",\n \"currency\": \"BRL\",\n \"current_price\": 23.77,\n \"target_price_6m\": 25.53,\n \"target_price_12m\": 26.74,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.6,\n \"thesis_bullets\": [\n \"Defensive pharmaceutical sector with stable demand.\",\n \"Strong operating margins and cash flow generation.\",\n \"EPS growth outpacing revenue, indicating efficiency gains.\",\n \"Reasonable valuation at current P/E with upside potential.\",\n \"Moderate debt and healthy balance sheet position.\"\n ],\n \"key_drivers\": [\n { \"driver\": \"Revenue growth from new products\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Margin expansion via cost efficiencies\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Regulatory approvals for drugs\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Competition from generics\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n { \"driver\": \"Currency exchange rate volatility\", \"impact\": \"LOW\", \"direction\": \"NEG\" },\n { \"driver\": \"Execution of acquisition strategies\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Healthcare spending trends in Brazil\", \"impact\": \"MED\", \"direction\": \"POS\" }\n ],\n \"risks\": [\n \"Regulatory changes affecting drug pricing.\",\n \"Increased competition in pharmaceutical market.\",\n \"Economic downturn reducing healthcare spending.\",\n \"Integration risks from recent acquisitions.\",\n \"Currency depreciation increasing input costs.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.05,\n \"ebit_margin_target\": 0.23,\n \"wacc\": 0.095,\n \"terminal_multiple\": 13\n },\n \"scenarios\": {\n \"bear\": { \"target_price\": 21.60, \"prob\": 0.3, \"notes\": \"Lower growth and multiple compression.\" },\n \"base\": { \"target_price\": 26.74, \"prob\": 0.5, \"notes\": \"Steady execution and moderate growth.\" },\n \"bull\": { \"target_price\": 32.26, \"prob\": 0.2, \"notes\": \"Strong growth and multiple expansion.\" }\n },\n \"method_notes\": \"Valuation based on earnings growth and P/E multiples. BUY due to 12% expected upside. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T21:30:33.000Z", "model": "Equity Research Model", "risks": [ "Regulatory changes affecting drug pricing.", "Increased competition in pharmaceutical market.", "Economic downturn reducing healthcare spending.", "Integration risks from recent acquisitions.", "Currency depreciation increasing input costs." ], "ticker": "HYPE3", "currency": "BRL", "scenarios": { "base": { "prob": 0.5, "notes": "Steady execution and moderate growth.", "target_price": 26.74 }, "bear": { "prob": 0.3, "notes": "Lower growth and multiple compression.", "target_price": 21.6 }, "bull": { "prob": 0.2, "notes": "Strong growth and multiple expansion.", "target_price": 32.26 } }, "confidence": 0.6, "assumptions": { "wacc": 0.095, "revenue_cagr_3y": 0.05, "terminal_multiple": 13, "ebit_margin_target": 0.23 }, "key_drivers": [ { "driver": "Revenue growth from new products", "impact": "HIGH", "direction": "POS" }, { "driver": "Margin expansion via cost efficiencies", "impact": "MED", "direction": "POS" }, { "driver": "Regulatory approvals for drugs", "impact": "MED", "direction": "POS" }, { "driver": "Competition from generics", "impact": "MED", "direction": "NEG" }, { "driver": "Currency exchange rate volatility", "impact": "LOW", "direction": "NEG" }, { "driver": "Execution of acquisition strategies", "impact": "HIGH", "direction": "POS" }, { "driver": "Healthcare spending trends in Brazil", "impact": "MED", "direction": "POS" } ], "method_notes": "Valuation based on earnings growth and P/E multiples. BUY due to 12% expected upside. Not investment advice.", "current_price": 23.77, "recommendation": "BUY", "thesis_bullets": [ "Defensive pharmaceutical sector with stable demand.", "Strong operating margins and cash flow generation.", "EPS growth outpacing revenue, indicating efficiency gains.", "Reasonable valuation at current P/E with upside potential.", "Moderate debt and healthy balance sheet position." ], "target_price_6m": 25.53, "target_price_12m": 26.74 }, "errorsJson": { "attempts": [], "providerMeta": { "endpoint": "https://api.deepseek.com/v1/chat/completions", "provider": "deepseek", "webSearch": { "enabled": false, "supported": false }, "responseFormat": "json_object" }, "sanityIssues": [] }, "latencyMs": 343, "createdAt": "2026-04-09T04:18:20.229Z", "usage": { "inputTokens": 2250, "outputTokens": 3791, "costUsd": 0.002222 } }, { "id": "cmnqyvhe100j9p658pz42td3g", "runId": "cmnqyvhdz00j6p658w3edkxay", "modelId": "gemini.3-pro", "status": "SUCCESS", "rawOutput": "{\"model\":\"Hypera_Equity_Model_v1\",\"as_of\":\"2026-04-08T21:30:33.000Z\",\"ticker\":\"HYPE3\",\"currency\":\"BRL\",\"current_price\":23.77,\"target_price_6m\":25.00,\"target_price_12m\":26.50,\"recommendation\":\"BUY\",\"confidence\":0.65,\"thesis_bullets\":[\"Resilient pharma demand supports stable cash flow generation.\",\"High dividend yield provides strong total return floor.\",\"Elevated leverage remains a key headwind for valuation.\",\"Margin expansion potential from recent portfolio acquisitions.\",\"Valuation is attractive at 12.8x PE given EPS growth.\"],\"key_drivers\":[{\"driver\":\"Selic rate changes\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"OTC market volume growth\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Prescription drug pricing power\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Raw material import costs\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Synergies from acquired brands\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Working capital optimization\",\"impact\":\"MED\",\"direction\":\"POS\"}],\"risks\":[\"High interest rates increasing debt servicing costs.\",\"Regulatory changes in drug pricing by CMED.\",\"FX volatility impacting imported active pharmaceutical ingredients.\",\"Increased competition from generic drug manufacturers.\"],\"assumptions\":{\"revenue_cagr_3y\":0.06,\"ebit_margin_target\":0.24,\"wacc\":0.125,\"terminal_multiple\":10.5},\"scenarios\":{\"bear\":{\"target_price\":19.50,\"prob\":0.25,\"notes\":\"High rates compress margins and leverage bites.\"},\"base\":{\"target_price\":26.50,\"prob\":0.55,\"notes\":\"Steady execution and moderate growth materialize.\"},\"bull\":{\"target_price\":31.00,\"prob\":0.20,\"notes\":\"Stronger OTC sales and successful deleveraging.\"}},\"method_notes\":\"DCF and EV/EBITDA multiple valuation. Target implies 11% upside, supporting a BUY rating. High leverage warrants caution. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T21:30:33.000Z", "model": "Hypera_Equity_Model_v1", "risks": [ "High interest rates increasing debt servicing costs.", "Regulatory changes in drug pricing by CMED.", "FX volatility impacting imported active pharmaceutical ingredients.", "Increased competition from generic drug manufacturers." ], "ticker": "HYPE3", "currency": "BRL", "scenarios": { "base": { "prob": 0.55, "notes": "Steady execution and moderate growth materialize.", "target_price": 26.5 }, "bear": { "prob": 0.25, "notes": "High rates compress margins and leverage bites.", "target_price": 19.5 }, "bull": { "prob": 0.2, "notes": "Stronger OTC sales and successful deleveraging.", "target_price": 31 } }, "confidence": 0.65, "assumptions": { "wacc": 0.125, "revenue_cagr_3y": 0.06, "terminal_multiple": 10.5, "ebit_margin_target": 0.24 }, "key_drivers": [ { "driver": "Selic rate changes", "impact": "HIGH", "direction": "NEG" }, { "driver": "OTC market volume growth", "impact": "MED", "direction": "POS" }, { "driver": "Prescription drug pricing power", "impact": "HIGH", "direction": "POS" }, { "driver": "Raw material import costs", "impact": "MED", "direction": "NEG" }, { "driver": "Synergies from acquired brands", "impact": "MED", "direction": "POS" }, { "driver": "Working capital optimization", "impact": "MED", "direction": "POS" } ], "method_notes": "DCF and EV/EBITDA multiple valuation. Target implies 11% upside, supporting a BUY rating. High leverage warrants caution. Not investment advice.", "current_price": 23.77, "recommendation": "BUY", "thesis_bullets": [ "Resilient pharma demand supports stable cash flow generation.", "High dividend yield provides strong total return floor.", "Elevated leverage remains a key headwind for valuation.", "Margin expansion potential from recent portfolio acquisitions.", "Valuation is attractive at 12.8x PE given EPS growth." ], "target_price_6m": 25, "target_price_12m": 26.5 }, "errorsJson": { "attempts": [], "providerMeta": { "model": "gemini-3-pro-preview", "provider": "gemini", "webSearch": { "used": false, "allowed": false, "enabled": false, "requested": false, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 29049, "createdAt": "2026-04-09T04:18:20.229Z", "usage": { "inputTokens": 2485, "outputTokens": 480, "costUsd": 0.01073 } }, { "id": "cmnqyvhe100j7p658re8narjc", "runId": "cmnqyvhdz00j6p658w3edkxay", "modelId": "openai.gpt-5.4", "status": "SUCCESS", "rawOutput": "{\"model\":\"AI Model Recommendation\",\"as_of\":\"2026-04-08T21:30:33.000Z\",\"ticker\":\"HYPE3\",\"currency\":\"BRL\",\"current_price\":23.77,\"target_price_6m\":24.6,\"target_price_12m\":25,\"recommendation\":\"HOLD\",\"confidence\":0.6,\"thesis_bullets\":[\"Defensive pharma portfolio supports resilient cash generation.\",\"Margins remain strong versus most domestic consumer-health peers.\",\"Low topline growth limits multiple rerating potential.\",\"High leverage constrains flexibility despite healthy free cash flow.\",\"Valuation looks reasonable, but not clearly discounted.\"],\"key_drivers\":[{\"driver\":\"OTC and prescription mix\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Brand pricing power\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Operating margin discipline\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Debt reduction pace\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Revenue growth reacceleration\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Dividend support\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Brazil interest rates\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Inventory/channel execution\",\"impact\":\"MED\",\"direction\":\"NEG\"}],\"risks\":[\"Slower prescription demand growth\",\"Higher refinancing costs\",\"Regulatory pricing pressure\",\"Execution missteps in portfolio integration\"],\"assumptions\":{\"revenue_cagr_3y\":6,\"ebit_margin_target\":23.5,\"wacc\":12.5,\"terminal_multiple\":9.5},\"scenarios\":{\"bear\":{\"target_price\":20.5,\"prob\":0.25,\"notes\":\"Growth stalls and deleveraging remains slow, compressing the earnings multiple.\"},\"base\":{\"target_price\":25,\"prob\":0.5,\"notes\":\"Steady brand growth and stable margins offset leverage concerns.\"},\"bull\":{\"target_price\":29.5,\"prob\":0.25,\"notes\":\"Faster sell-out growth and balance-sheet improvement drive rerating.\"}},\"method_notes\":\"Blended normalized P/E and EV/EBITDA view using snapshot fundamentals; quote fields kept exactly from snapshot. High dividend supports total return, but price upside alone is only modest, so HOLD fits. No sell-side targets used. not investment advice\"}", "parsedJson": { "as_of": "2026-04-08T21:30:33.000Z", "model": "AI Model Recommendation", "risks": [ "Slower prescription demand growth", "Higher refinancing costs", "Regulatory pricing pressure", "Execution missteps in portfolio integration" ], "ticker": "HYPE3", "currency": "BRL", "scenarios": { "base": { "prob": 0.5, "notes": "Steady brand growth and stable margins offset leverage concerns.", "target_price": 25 }, "bear": { "prob": 0.25, "notes": "Growth stalls and deleveraging remains slow, compressing the earnings multiple.", "target_price": 20.5 }, "bull": { "prob": 0.25, "notes": "Faster sell-out growth and balance-sheet improvement drive rerating.", "target_price": 29.5 } }, "confidence": 0.6, "assumptions": { "wacc": 12.5, "revenue_cagr_3y": 6, "terminal_multiple": 9.5, "ebit_margin_target": 23.5 }, "key_drivers": [ { "driver": "OTC and prescription mix", "impact": "HIGH", "direction": "POS" }, { "driver": "Brand pricing power", "impact": "HIGH", "direction": "POS" }, { "driver": "Operating margin discipline", "impact": "HIGH", "direction": "POS" }, { "driver": "Debt reduction pace", "impact": "HIGH", "direction": "NEG" }, { "driver": "Revenue growth reacceleration", "impact": "MED", "direction": "POS" }, { "driver": "Dividend support", "impact": "MED", "direction": "POS" }, { "driver": "Brazil interest rates", "impact": "MED", "direction": "NEG" }, { "driver": "Inventory/channel execution", "impact": "MED", "direction": "NEG" } ], "method_notes": "Blended normalized P/E and EV/EBITDA view using snapshot fundamentals; quote fields kept exactly from snapshot. High dividend supports total return, but price upside alone is only modest, so HOLD fits. No sell-side targets used. not investment advice", "current_price": 23.77, "recommendation": "HOLD", "thesis_bullets": [ "Defensive pharma portfolio supports resilient cash generation.", "Margins remain strong versus most domestic consumer-health peers.", "Low topline growth limits multiple rerating potential.", "High leverage constrains flexibility despite healthy free cash flow.", "Valuation looks reasonable, but not clearly discounted." ], "target_price_6m": 24.6, "target_price_12m": 25 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "openai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "resp_0cf6455456b8e3290069d72a68409c81939af89464be3c4af6", "reasoningEffort": "medium", "structuredOutputs": { "used": true, "requested": true, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 17642, "createdAt": "2026-04-09T04:18:20.229Z", "usage": { "inputTokens": 2468, "outputTokens": 995, "costUsd": 0.018249 } }, { "id": "cmnqyvhe100jap6584o8jtko2", "runId": "cmnqyvhdz00j6p658w3edkxay", "modelId": "xai.grok-4.20-reasoning", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Equity Research Model\",\n \"as_of\": \"2026-04-08T21:30:33.000Z\",\n \"ticker\": \"HYPE3\",\n \"currency\": \"BRL\",\n \"current_price\": 23.77,\n \"target_price_6m\": 25.2,\n \"target_price_12m\": 27.0,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.62,\n \"thesis_bullets\": [\n \"Strong brands drive stable pharma revenue in Brazil\",\n \"High 9.8% dividend yield supports total returns\",\n \"Solid cash flow covers debt and capex needs\",\n \"Reasonable 12.8x PE versus sector averages\",\n \"Modest growth offset by efficiency gains\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Brazil OTC pharma demand\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"New product pipeline\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Operational cost efficiencies\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Generic drug competition\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Regulatory pricing caps\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Dividend payout sustainability\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"BRL currency volatility\",\n \"impact\": \"LOW\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Interest rate environment\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n }\n ],\n \"risks\": [\n \"Intensifying generic competition\",\n \"Adverse drug pricing regulations\",\n \"Higher interest expense on debt\",\n \"Slower than expected revenue growth\",\n \"Portfolio integration risks\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 7,\n \"ebit_margin_target\": 24,\n \"wacc\": 10,\n \"terminal_multiple\": 12\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 19.5,\n \"prob\": 0.3,\n \"notes\": \"Low growth and margin compression from regulation.\"\n },\n \"base\": {\n \"target_price\": 27,\n \"prob\": 0.5,\n \"notes\": \"Steady execution and dividends drive fair upside.\"\n },\n \"bull\": {\n \"target_price\": 33,\n \"prob\": 0.2,\n \"notes\": \"Strong launches and market share gains accelerate.\"\n }\n },\n \"method_notes\": \"DCF valuation anchored on 7% revenue CAGR, 24% EBIT margin, 10% WACC and 12x terminal multiple. 13% 12M upside plus high yield supports BUY per rubric. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T21:30:33.000Z", "model": "AI Equity Research Model", "risks": [ "Intensifying generic competition", "Adverse drug pricing regulations", "Higher interest expense on debt", "Slower than expected revenue growth", "Portfolio integration risks" ], "ticker": "HYPE3", "currency": "BRL", "scenarios": { "base": { "prob": 0.5, "notes": "Steady execution and dividends drive fair upside.", "target_price": 27 }, "bear": { "prob": 0.3, "notes": "Low growth and margin compression from regulation.", "target_price": 19.5 }, "bull": { "prob": 0.2, "notes": "Strong launches and market share gains accelerate.", "target_price": 33 } }, "confidence": 0.62, "assumptions": { "wacc": 10, "revenue_cagr_3y": 7, "terminal_multiple": 12, "ebit_margin_target": 24 }, "key_drivers": [ { "driver": "Brazil OTC pharma demand", "impact": "HIGH", "direction": "POS" }, { "driver": "New product pipeline", "impact": "MED", "direction": "POS" }, { "driver": "Operational cost efficiencies", "impact": "MED", "direction": "POS" }, { "driver": "Generic drug competition", "impact": "HIGH", "direction": "NEG" }, { "driver": "Regulatory pricing caps", "impact": "MED", "direction": "NEG" }, { "driver": "Dividend payout sustainability", "impact": "HIGH", "direction": "POS" }, { "driver": "BRL currency volatility", "impact": "LOW", "direction": "NEG" }, { "driver": "Interest rate environment", "impact": "MED", "direction": "NEG" } ], "method_notes": "DCF valuation anchored on 7% revenue CAGR, 24% EBIT margin, 10% WACC and 12x terminal multiple. 13% 12M upside plus high yield supports BUY per rubric. Not investment advice.", "current_price": 23.77, "recommendation": "BUY", "thesis_bullets": [ "Strong brands drive stable pharma revenue in Brazil", "High 9.8% dividend yield supports total returns", "Solid cash flow covers debt and capex needs", "Reasonable 12.8x PE versus sector averages", "Modest growth offset by efficiency gains" ], "target_price_6m": 25.2, "target_price_12m": 27 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "xai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "2b8d1a64-c94d-960d-9acc-906424117696", "usedFallbackChatCompletions": false }, "sanityIssues": [] }, "latencyMs": 17550, "createdAt": "2026-04-09T04:18:20.229Z", "usage": { "inputTokens": 2810, "outputTokens": 2759, "costUsd": 0.049815 } } ] } }